Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. (COPN.SW) Stock Competitors & Peer Comparison
See (COPN.SW) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| COPN.SW | CHF 86.90 | +0.58% | 1.4B | -413.81 | -CHF 0.21 | +2.21% |
| LLY.SW | CHF 720.00 | -7.69% | 554.8B | 39.60 | CHF 18.18 | +0.68% |
| RO.SW | CHF 332.00 | +0.73% | 264.3B | 20.69 | CHF 16.05 | +3.08% |
| ROG.SW | CHF 322.30 | +0.50% | 256.6B | 20.11 | CHF 16.03 | +3.04% |
| NOVN.SW | CHF 123.20 | +0.24% | 235.1B | 21.54 | CHF 5.72 | +1.95% |
| GSK.SW | CHF 19.98 | N/A | 101.6B | 18.76 | CHF 1.07 | N/A |
| BAYN.SW | CHF 36.97 | +0.00% | 36.3B | -11.13 | -CHF 3.32 | +0.28% |
Stock Comparison
COPN.SW vs LLY.SW Comparison April 2026
COPN.SW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COPN.SW stands at 1.4B. In comparison, LLY.SW has a market cap of 554.8B. Regarding current trading prices, COPN.SW is priced at CHF 86.90, while LLY.SW trades at CHF 720.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COPN.SW currently has a P/E ratio of -413.81, whereas LLY.SW's P/E ratio is 39.60. In terms of profitability, COPN.SW's ROE is -0.01%, compared to LLY.SW's ROE of +0.98%. Regarding short-term risk, COPN.SW is more volatile compared to LLY.SW. This indicates potentially higher risk in terms of short-term price fluctuations for COPN.SW.Check LLY.SW's competition here